Andere talen NetraMark Holdings Inc. OTC Markets

Aandelen

AINMF

CA64119M1059

Beurs gesloten - OTC Markets Andere beurzen 20:05:14 11-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,205 ^USD	-3,21%		-6,61%	-22,17%

10/06	NetraMark Holdings Inc. Kondigt een samenwerkingsovereenkomst aan met het National Institute of Mental Health voor het analyseren van klinische onderzoeksgegevens over het gebruik van ketamine bij psychische stoornissen	CI
14/05	NetraMark Holdings Inc. Rapporteert resultaten voor het tweede kwartaal en de zes maanden eindigend op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

NetraMark Holdings Inc. Announces Collaboration Agreement with National Institute of Mental Health to Analyze Clinical Trial Data on the Use of Ketamine in Mental Disorders	10/06
NETRAMARK ANNOUNCES COLLABORATION AGREEMENT WITH NIMH TO ANALYZE CLINICAL TRIAL DATA ON THE USE OF KETAMINE IN PSYCHIATRIC DISORDERS	10/06
257,550 Common Share of Nurosene Health Inc. are subject to a Lock-Up Agreement Ending on 9-JUN-2024.	09/06
30,000 Options of Nurosene Health Inc. are subject to a Lock-Up Agreement Ending on 9-JUN-2024.	09/06
NETRAMARK TO INTRODUCE THE TREATMENT ATTITUDE PROFILE (TAP™) SCALE FOR PLACEBO RESPONSE PERSONA DISCOVERY USING ITS NETRA AI TECHNOLOGY AT THE 2024 ASCP ANNUAL MEETING	28/05
NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	14/05
NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES NOVEL LUNG AND COLON CANCER BIOMARKERS AND PATIENT SUBPOPULATIONS	10/04
Netramark's Ai-Based Clinical Solution Identifies Novel Lung and Colon Cancer Biomarkers and Patient Subpopulations	10/04
NETRAMARK ANNOUNCES SHAREHOLDER MEETING RESULTS	05/04
PHARMACEUTICAL INDUSTRY VETERAN JOINS NETRAMARK ADVISORY BOARD	04/04
NetraMark Holdings Inc. announces appointment of Jeff Huntsman to its strategic advisory board	04/04
NETRAMARK PROVIDES BUSINESS UPDATE AND HIGHLIGHTS PROGRESS	02/04
NETRAMARK SIGNS CONTRACT WITH PHARMACEUTICAL COMPANY TO DELIVER CLINICAL TRIAL INSIGHTS REGARDING EFFICACY AND PLACEBO RESPONSE	12/03
NetraMark Holdings Inc. Signs Contract with Pharmaceutical Company to Deliver Clinical Trial Insights Regarding Efficacy and Placebo Response	12/03
NetraMark Presenting New Data Showing Ability of its Proprietary NetraAI Clinical Trial Solution in PD Insights	11/03
NETRAMARK'S AI-BASED CLINICAL SOLUTION IDENTIFIES PARKINSON'S DISEASE SUBTYPES LINKED BY MITOCHONDRIAL, MICROBIOME AND IMMUNE SIGNALING	11/03
NetraMark Holdings Inc. Announces the Presentation of New Data Demonstrating the Ability of its Proprietary NetraAI Clinical Trial Solution	11/03
NETRAMARK TO PRESENT NEW DATA HIGHLIGHTING THE UTILITY OF IT'S AI-BASED CLINICAL SOLUTION IN IDENTIFYING PARKINSON'S DISEASE ASSOCIATED BIOMARKERS AT AD/PD™ 2024	29/02
NetraMark Holdings Inc. Signs Fourth Contract with Large Biopharmaceutical Company to Enhance Clinical Trial	27/02
NETRAMARK SIGNS FOURTH CONTRACT WITH LARGE BIOPHARMACEUTICAL COMPANY TO ENHANCE CLINICAL TRIAL INSIGHTS	27/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen NetraMark Holdings Inc. OTC Markets

Aandelen

AINMF

CA64119M1059

Andere talen

Filters